Dual antiplatelet therapy with aspirin and a P2Y12 receptor antagonist is standard of care in acute coronary syndrome and is recommended for a period of 12months regardless of invasive revascularization. The antiplatelet action of these agents is governed by levels of active plasma metabolites, which may be influenced by genetic variations. Recently genotyping has gained considerable attention to identify patients who may demonstrate poor platelet responsiveness, as a potential method to improve long-term outcomes. However whether or not systematic genotyping will prove to be advantageous and cost-effective is the subject of on-going studies. This chapter discusses the current data on the impact of genetic variations with antiplatelet therapy, as well as the potential role of genotyping in prescription of antiplatelet therapies in acute coronary syndrome.
|Title of host publication||Cardiovascular Diseases|
|Subtitle of host publication||Genetic Susceptibility, Environmental Factors and their Interaction|
|Number of pages||31|
|State||Published - 19 Aug 2016|
- Gain-of-function alleles
- Loss-of-function alleles